The consortium is slated to gather French companies, research labs and clinical centers to aid in the development of AI in the imaging space.
With €13 million in funding from the “Investments for the Future” program led by the French General Secretariat for Investment and operated by Bpifrance, the consortium’s goals inclue improving diagnosis accuracy, patient care pathways and the efficiency of healthcare systems overall, according to a news release.
For the program, GE Healthcare plans to develop an advanced visualization platform, a software development kit for clinical, therapeutic and/or research applications and a technology framework that meets regulatory requirements for developing medical applications.
The company is leading the consortium with participation from SME Evolucare, Therapanacea, Pixyl, Institut Curie, French Paris group of hospital AP-HP, leading European Cancer Center Gustave Roussy and the Paris Hospital Saint Joseph Foundation who will partner on clinical case studies in an effort to accelerate the AI projects.
A number of applications are already under development as part of the project, including ones focused on managing liver cancer with AI characterization tools, as well as diagnosis and prognosis of lung diseases and the accuracy and personalization of treatments for brain cancer.
The program is leveraging GE Healthcare’s Edison intelligence platform and aims to eventually offer the implementation of the technologies to other partners using medical imaging.
“Our aim is to create the tools that will facilitate large scale data annotation and algorithm design, testing and validation to cut cycle development time for AI start-ups, researchers or radiologists who wish to create AI applications for medical imaging,” GE Healthcare’s AI DReAM project leader Baptiste Perrin said in the news release.